Patents by Inventor Scott Max Herbig

Scott Max Herbig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS
    Publication number: 20220142927
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 12, 2022
    Applicant: PFIZER INC.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C. Stock
  • Tofacitinib oral sustained release dosage forms
    Patent number: 11253523
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: February 22, 2022
    Assignee: Pfizer Inc.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C. Stock
  • TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS
    Publication number: 20200206232
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Applicant: PFIZER INC.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C. Stock
  • Tofacitinib oral sustained release dosage forms
    Patent number: 10639309
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: May 5, 2020
    Assignee: Pfizer Inc.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C. Stock
  • TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS
    Publication number: 20180193347
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Application
    Filed: March 8, 2018
    Publication date: July 12, 2018
    Applicant: PFIZER INC.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, Manisha Lamba, Thomas C. Stock
  • Tofacitinib oral sustained release dosage forms
    Patent number: 9937181
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 10, 2018
    Assignee: Pfizer Inc.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C Stock
  • TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS
    Publication number: 20140271842
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Pfizer Inc.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C Stock
  • METHODS, DOSAGE FORMS AND KITS FOR ADMINISTERING ZIPRASIDONE WITHOUT FOOD
    Publication number: 20110002989
    Abstract: The present invention provides methods, dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment, the invention relates to a method for treating a CNS disorder in a human, which method comprises administering to the human in a fasted state, a solid oral dosage form comprising an amount of ziprasidone effective to treat said CNS disorder, wherein the area under the serum concentration versus time curve (AUC0-inf) of the ziprasidone in the human subsequent to said administering is from 70% to 140% of the mean area under the ziprasidone serum concentration versus time curve (AUC0-inf) resulting from administration of a control ziprasidone immediate release oral capsule containing the same amount of ziprasidone to a cohort of humans in a fed state.
    Type: Application
    Filed: March 4, 2009
    Publication date: January 6, 2011
    Inventors: William John Curatolo, Scott Max Herbig, Avinash Govind Thombre, Jaymin Chandrakant Shah, Sheri L. Shamblin, Timothy Lukas, William Brett Caldwell, Dwayne Thomas Friesen, David Keith Lyon, Christopher Donovan Craig
  • Solubilized sertraline compositions
    Publication number: 20040208926
    Abstract: Compositions of matter comprising sertraline and a solubilizing agent which increases the solubility of sertraline in aqueous chloride ion-containing use environments.
    Type: Application
    Filed: May 4, 2004
    Publication date: October 21, 2004
    Applicant: Pfizer Inc
    Inventors: Dwayne Thomas Friesen, Scott Max Herbig, Ravi Mysore Shanker, James Blair West
  • Sertraline salts and sustained-release dosage forms of sertraline
    Patent number: 6517866
    Abstract: Sustained release dosage forms of sertraline which release sertraline at a rate between 1 mgA/hr and 40 mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is released at a rate less than 1 mgA/hr.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: February 11, 2003
    Assignee: Pfizer Inc.
    Inventors: Mary Tanya Am Ende, William John Curatolo, Hylar Lewis Friedman, Dwayne Thomas Friesen, Scott Max Herbig, Ravi Mysore Shankar, James Blair West
  • Use of interfacially-polymerized membranes in delivery devices
    Patent number: 5876752
    Abstract: Devices for controlled release of active substances in the form of tablets, capsules and beads comprised of a porous substructure surrounded by one or more interfacial membranes.
    Type: Grant
    Filed: February 3, 1993
    Date of Patent: March 2, 1999
    Assignee: Pfizer Inc.
    Inventors: Scott Max Herbig, Richard Wilker Korsmeyer, Avinash Govind Thombre